secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2026-05-14T20:15:44+00:00
Accession:  0001493152-26-023094
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics Q1 2026 net loss narrows to $4.4M; cash $6.6M, CLD-401 IND on track
--------------------------------------------------------------------------------

- Net loss attributable to common shareholders: $4.4M ($0.43/shr) vs $5.0M ($2.21/shr) in Q1 2025.
- Cash and restricted cash $6.8M as of Mar 31, 2026; up from $5.8M at Dec 31, 2025.
- G&A expenses fell $1.0M to $1.6M; R&D expenses rose to $2.6M from $2.4M.
- CLD-401 IND submission expected by end of 2026; AACR data showed T, NK, and γδ T-cell activation.
- Entered partnership with TransferAI to use AI platform to streamline CLD-401 IND submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226023094/0001493152-26-023094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226023094/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-023094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer